Respiratory syncytial virus immunisation
Not yet recruitingSafety, Tolerability and Immunogenicity of RSV prefusion F protein 847a and 847b Vaccine in Children 5‑17 Years at High Risk of RSV Disease
Safety, Tolerability and Immunogenicity of RSV prefusion F protein 847a and 847b Vaccine in Children 5‑17 Years at High Risk of RSV Disease
- Disease:Respiratory syncytial virus immunisation
- Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847ARESPIRATORY SYNCYTIAL VIRUS, SUBGROUP B, STABILIZED PREFUSION F PROTEIN 847B
Poland- Participants:0–17 years
- Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
- Sponsor:Pfizer Inc.

